ClinicalTrials.gg
RecruitingNCT07454070Updated Jun 16, 2026

Efficacy of Transcutaneous Auricular Vagus Nerve Stimulation on Alleviating Major Depressive Disorder in Patients With Acute Coronary Syndrome After Percutaneous Coronary Intervention:A Prospective, Double-Blind,Randomized Controlled Study

An interventional study of Transcutaneous Auricular Vagus Nerve Stimulation (taVNS) Intervention and sham Transcutaneous Auricular Vagus Nerve Stimulation (taVNS) Control in Depressive Disorder (Per DSM-V Criteria, Mild-to-moderate), Acute Coronary Syndrome (ACS) and Percutaneous Coronary Intervention (PCI), sponsored by Jing Han. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-16.

Sponsored by Jing Han · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jan 2026; still recruiting 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 54 studies in Depressive Disorder with a site in China — 21 open to participants now, 23 under way, 2 of them phase 3. Depressive Disorder · China.

Planned enrollment
21st of 42
120 · median 120
Started
2026
with 10 others
No phase
28 of 54
12 open now
Primary completion
2026-06
later than 10 of 22 live
Registered
45th of 54
by date

Among the 54 studies in Depressive Disorder with a site in China, this one is the 21st largest by planned enrollment of the 42 interventional ones that give a count, is one of 11 that started in 2026, is one of 28 with no phase, reaches primary completion later than 10 of the 22 other live ones, and was the 45th registered.

Depressive Disorder

857 studies on the registry are indexed under Depressive Disorder; 160 are open to participants now.

Browse Depressive Disorder studies →

Open to participants now

21 of the 54 studies in Depressive Disorder with a site in China are open now. Recruiting first, the newest first:

15 more — sign in →

All 21 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 116 Depressive Disorder studies recruiting now, 44 (38%) set no upper age limit and 66 (57%) stop at 75 or younger; 24 take children under 18; 25 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies in Depressive Disorder with a site in China, or all of them as a file.
02

Study summary

This is a randomized, controlled study. ACS follow- up patients aged 18 to 80 years old with hemodynamic stability, who are 14 days to 1 year after PCI, are screened through the HAMD score and the HAMA score. Patients with a HAMD score greater than 7 points and a HAMD score higher than that of the HAMA, are included in this study.

Patients were allocated to the active taVNS group or sham taVNS group with a 1:1 ratio. Both groups received the stimulation for 20 minutes each time, twice a day with an 8-week treatment and a 8-week follow-up.

All treatments were self-administered by the patients at home after they received training from the hospitals.

The primary observation endpoints include the depression scores of the HAMD. The secondary observation endpoints include the HAMA 、GAD、 response and remission rates of HAMD ,as well as the PCL-C for post-traumatic stress disorder. We also observed the cardiac function indexes measured by echocardiography and the B-type natriuretic peptide .

Read the detailed description

I. Background and Rationale Acute Coronary Syndrome (ACS) is a severe form of coronary artery disease characterized by the rupture or erosion of atherosclerotic plaques, followed by the formation of occlusive or non-occlusive thrombi. Encompassing unstable angina, acute ST-segment elevation myocardial infarction, and non-ST-segment elevation myocardial infarction, ACS remains a leading cause of morbidity and mortality globally. Percutaneous Coronary Intervention (PCI) is a cornerstone therapeutic strategy for ACS, enabling rapid revascularization and myocardial reperfusion. However, as an invasive procedure, combined with patients' concerns regarding postoperative complications, stent longevity, medication side effects, and treatment costs, PCI is frequently associated with significant emotional disturbances in the postoperative period.

Meta-analyses have shown that the prevalence of depression among post-PCI patients ranges from 20% to 82%, while the incidence of anxiety is between 25% and 37%. Notably, the rates of depression and anxiety can surge to 44.7% and 54.7%, respectively, on the first day after PCI. Clinical evidence confirms that post-PCI depression and anxiety substantially reduce treatment adherence and increase the risk of Major Adverse Cardiovascular Events (MACE): patients with anxiety face a 3.742-fold higher risk of MACE compared to those without anxiety, while depressed patients have a 3.087-fold higher risk, and the combined effect of anxiety and depression elevates this risk to 7.303-fold. These emotional disorders are thus recognized as crucial predictors of poor prognosis in post-PCI patients. Nevertheless, conventional antidepressant therapies have inherent limitations: antidepressant medications yield a response rate of only 50%-67%, require at least 4 weeks to exert therapeutic effects, and are associated with common side effects such as nausea, cardiovascular reactions, and sexual dysfunction, leading to poor medication adherence. Cognitive behavioral therapy, on the other hand, is hindered by its complexity and high cost, limiting its accessibility in primary care settings.

Vagus Nerve Stimulation (VNS) is an FDA-approved somatic therapy for treatment-resistant depression (TRD), demonstrating clinically significant antidepressant efficacy. However, invasive VNS (iVNS) is less appealing due to surgical risks, high costs (ranging from $30,000 to $50,000), and potential side effects, resulting in low clinical utilization. To overcome these barriers, non-invasive transcutaneous auricular Vagus Nerve Stimulation (taVNS) has been developed and garnered increasing attention. Anatomical studies have identified the ear as the only body surface region innervated by afferent vagus nerve fibers. Based on the "bottom-up" mechanism of the central nervous system, electrical stimulation propagates retrogradely from peripheral nerves to brainstem and central structures, mimicking the antidepressant effects of conventional VNS without the burden of surgical intervention. Since the first clinical study on taVNS for depression in 2009, a series of trials have validated its efficacy in ameliorating depressive symptoms. However, research on taVNS for treating depression in ACS patients after PCI remains scarce. Therefore, this randomized controlled trial aims to investigate the efficacy and safety of taVNS in this specific population, providing a novel therapeutic option for clinical practice.

II. Study Objectives (A) Primary Objective To evaluate the antidepressant efficacy of transcutaneous auricular Vagus Nerve Stimulation (taVNS) in ACS patients with mild-to-moderate depression after PCI, using the change in Hamilton Depression Rating Scale (HAMD-17) scores from baseline to week 8 as the primary outcome measure.

(B) Secondary Objectives To assess the effects of taVNS on anxiety, post-traumatic stress disorder (PTSD), and quality of life in the study population; To observe the impacts of taVNS on physiological indicators, including heart rate variability (HRV), cardiac function, and inflammatory factors; To verify the clinical safety of taVNS (adverse events, MACE incidence) and relevant efficacy metrics (HAMD response rate, remission rate).

III. Study Endpoints (A) Primary Endpoint Change in Hamilton Depression Rating Scale (HAMD-17) scores from baseline to week 8: The HAMD-17 is a validated tool for assessing depressive symptoms, with the following grading criteria: no depression (total score ≤7), mild depression (8-17), moderate depression (18-24), and severe depression (>24). The difference between week 8 and baseline scores directly reflects the degree of improvement in depressive symptoms.

(B) Secondary Endpoints Depression-related indicators: HAMD response rate (≥50% reduction in scores from baseline to week 8), HAMD remission rate (total score ≤7 at week 8), and change in Beck Depression Inventory (BDI) scores from baseline (BDI criteria: no depression [0-4], mild depression [5-7], moderate depression [8-15], severe depression [≥16]); Anxiety-related indicators: Change in Hamilton Anxiety Rating Scale (HAMA) scores from baseline (HAMA criteria: severe anxiety [≥29], marked anxiety [21-28], definite anxiety [14-20], possible anxiety [8-13], no anxiety [\<7]) and change in Generalized Anxiety Disorder-7 (GAD-7) scores from baseline (GAD-7 criteria: no generalized anxiety [0-4], mild [5-9], moderate [10-14], severe [15-21]); Other psychological indicators: Change in Posttraumatic Stress Disorder Checklist-Civilian Version (PCL-C) scores from baseline (PCL-C criteria: no significant symptoms [17-37], mild-to-moderate symptoms [38-49], significant symptoms [50-85]) and change in 36-Item Short Form Health Survey (SF-36) scores from baseline (comprising 8 domains, scored on a 100-point scale, with higher scores indicating better quality of life); Physiological indicators: Change in heart rate variability (HRV, including time-domain parameters such as SDNN and SDANN, and frequency-domain parameters such as TP and HF) from baseline; change in echocardiographic indices (left ventricular end-diastolic/systolic diameter, left ventricular ejection fraction) from baseline; change in venous blood markers (cardiac troponin I, N-terminal pro-B-type natriuretic peptide [NT-proBNP], interleukin-1 [IL-1], interleukin-6 [IL-6], tumor necrosis factor-α [TNF-α], C-reactive protein [CRP]) from baseline; Clinical outcomes: Incidence of Major Adverse Cardiovascular Events (MACE) during the intervention period (up to the 16-week follow-up), including death, myocardial infarction, and target vessel revascularization (as defined by the Academic Research Consortium [ARC] criteria).

IV. Study Population (A) Inclusion Criteria Age ≥18 years; Meeting the diagnostic criteria for ACS; 14 days to 12 months after successful PCI, with stable vital signs; Meeting the diagnostic criteria for depression according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V); HAMD-17 score ≥7 and \<24 (mild-to-moderate depression), with HAMA score \<HAMD score; Refusal of psychiatric consultation, antidepressant medication, or psychological therapy by the patient or their legal representative after full informed consent; Voluntary participation in the study and signing of the informed consent form. (B) Exclusion Criteria Severe heart failure (New York Heart Association [NYHA] class ≥III); Uncontrolled hypertension (systolic blood pressure ≥180 mmHg and diastolic blood pressure ≥110 mmHg); Electrocardiographic abnormalities (first-degree atrioventricular block with PR interval ≥0.20 s, second-degree type II or third-degree atrioventricular block at any time, 24-hour average heart rate ≤50 beats per minute, RR interval ≥3 s) or a history of syncope unrelated to the current ACS; Dialysis-dependent patients; Previous renal sympathetic denervation or vagal ganglion ablation; Expected survival time \<4 months; Pre-PCI diagnosis of severe mental illnesses, including schizophrenia, severe intellectual disability, or substance abuse; Current use of antipsychotic medications; High suicide risk; Pregnant or lactating women; Left ear diseases, acute exacerbation of asthma or chronic obstructive pulmonary disease, or other conditions precluding taVNS treatment; Implanted cardiac pacemaker, implantable cardioverter-defibrillator (ICD), or other implantable stimulators (e.g., vagus nerve stimulator, deep brain stimulator).

(C) Withdrawal Criteria Voluntary withdrawal by the patient for any reason or desire to pursue alternative therapies; Poor treatment adherence (taVNS completion rate \<80%) or severe non-compliance with lifestyle interventions (e.g., heavy smoking, excessive alcohol consumption) during follow-up; Development of new severe diseases after PCI that may affect the assessment of study endpoints; Loss to follow-up (failure to complete two consecutive follow-ups with no available contact).

V. Study Design and Intervention Protocol (A) Grouping Design Randomization method: Stratified block randomization will be used to assign patients to the active stimulation group (Group A) and the sham stimulation group (Group B) at a 1:1 ratio. Stratification will be based on age (18-60 years, >60 years) and gender (male, female), resulting in 4 subgroups. Random sequences with variable block sizes will be generated using R software.

Concealment of random allocation: Random sequences will be generated and stored by personnel not involved in the trial. After confirming patient eligibility, investigators will obtain allocation information via a central telephone randomization system to ensure allocation concealment.

Blinding design: A double-blind design will be adopted, with blinding of patients, investigators, and data analysts.

(B) Intervention Measures

All patients will receive standard ACS treatment and routine medications for secondary prevention of coronary heart disease, with the following additional interventions:

Active stimulation group (Group A): Transcutaneous auricular Vagus Nerve Stimulation (taVNS) using the Xidian Keyue BS-TVNS600 device. Operational procedure: Disinfection of electrodes and the target area of the left ear with 75% alcohol → abrasion of the left cymba concha and tragus with abrasive paste → re-disinfection with alcohol → application of conductive gel to electrodes → placement of electrodes on the left tragus → gradual increase of current to the patient's tolerable threshold. Parameter settings: Pulse frequency 20 Hz, pulse width 250 ms, current 0.5-3 mA, stimulation cycle (30 s on, 30 s off). Treatment frequency: Twice daily, 20 minutes per session, for 8 consecutive weeks.

Sham stimulation group (Group B): Sham taVNS treatment with the same device, wearing method, and parameter adjustments as Group A. However, stimulation will only be delivered for the first 5 seconds, with no subsequent electrical output. Treatment frequency will be identical to that of Group A.

(C) Patient Training and Management All patients will receive training on device operation (power on/off, electrode application, stimulation site positioning, intensity adjustment) and will perform self-administration at home. A diary card will be provided to record daily treatment date, duration, adverse events, and suggestions, which will be reviewed during follow-up. During the follow-up period, patients will also receive medication guidance and lifestyle interventions (popularization of coronary heart disease knowledge, diet and exercise advice, sleep guidance, smoking cessation, alcohol restriction, and weight management).

VI. Study Procedures and Follow-Up Schedule (A) Enrollment Process Outpatients or inpatients who are 2 weeks to 12 months after ACS PCI will undergo DSM-V diagnosis and HAMD/HAMA assessments by psychiatric physicians. Patients with mild-to-moderate depression who refuse conventional antidepressant treatment will be further screened against inclusion and exclusion criteria. Eligible patients will sign the informed consent form, undergo baseline data collection (scale assessments: HAMD, HAMA, BDI, GAD-7, PCL-C, SF-36; physiological tests: HRV, echocardiography, venous blood tests), be randomly assigned to a group, and initiate intervention.

(B) Follow-Up Schedule Week 4: Scale assessments (HAMD, HAMA, BDI, GAD-7, PCL-C, SF-36), vital sign monitoring, adverse event recording, and diary card review; Week 8: Scale assessments (same as week 4), HRV testing, venous blood tests, adverse event recording, and diary card review (primary follow-up point for assessing the primary endpoint); Week 12: Scale assessments (same as week 4), echocardiography, adverse event recording, and evaluation of lifestyle improvements; Week 16: Scale assessments (same as week 4), HRV testing, venous blood tests, collection of MACE data, adverse event recording, and study conclusion (final follow-up).

VII. Safety Management (A) Definition and Grading of Adverse Events Adverse event: Any unfavorable medical occurrence in a subject after intervention, including symptoms, diseases, or laboratory abnormalities, regardless of causal relationship with the intervention; Serious adverse event: An adverse event involving death, life-threatening conditions, permanent or severe disability/incapacity, hospitalization or prolonged hospitalization, or congenital anomalies/birth defects; Grading: Mild (tolerable, no special treatment required), moderate (intolerable, requiring special treatment), severe (life-threatening, requiring emergency treatment).

(B) Recording and Reporting of Adverse Events Adverse events will be documented in detail, including onset time, clinical manifestations, treatment course, duration, and outcome; Laboratory abnormalities will be followed up until recovery to normal levels, baseline values, or confirmation of no association with the intervention; Serious adverse events will be reported to the clinical research center and ethics committee within 24 hours.

(C) Risk Prevention Measures The clinical trial will be initiated only after obtaining approval in accordance with regulatory requirements; Strict implementation of inclusion and exclusion criteria to minimize baseline risks; Enhanced patient training on device operation to reduce human-induced risks; Appointment of a quality control supervisor (familiar with taVNS operation) to promptly address treatment-related risks; Provision of an emergency contact number for patients to ensure timely communication and management of adverse events.

VIII. Data Management and Statistical Analysis (A) Data Management Data will be entered using Excel software with double data entry and verification to ensure accuracy; A data access permission system will be established, allowing only authorized personnel to access and modify data; Data will be backed up twice (locally and in the cloud) and regularly verified to prevent loss or tampering; Logical checks will be performed after data entry, with abnormal data traced and corrected promptly.

(B) Statistical Analysis Sample size calculation: This randomized controlled trial will adopt a significance level (α) of 0.05 and a power (1-β) of 0.80. Based on a reported effect size of 57% for taVNS in alleviating depression, PASS software estimates a baseline sample size of 50 patients per group (100 total). Considering a 10% dropout/loss-to-follow-up rate and the need for stratification by age and gender, the final sample size will be 120 patients (60 per group).

Analysis populations:

Intent-to-Treat (ITT) set: All randomly assigned patients who receive at least one intervention will be included. Primary efficacy analysis will be performed according to the initial grouping to retain the advantages of randomization and reduce bias; Per-Protocol (PP) set: Patients who complete the full treatment course without major protocol violations (e.g., non-compliance with inclusion/exclusion criteria, receipt of interfering treatments, adherence rate \<80%, key follow-up beyond the time window) will be included for sensitivity analysis to verify the robustness of results.

Statistical methods:

Continuous data (scale scores, physiological indicators, etc.): Normally distributed data will be presented as "mean ± standard deviation" and compared using independent samples t-tests; non-normally distributed data will be presented as "median (interquartile range)" and compared using Wilcoxon rank-sum tests; Categorical data (HAMD response rate/remission rate, MACE incidence, etc.): Presented as "n (%)" and compared using chi-square tests; The primary endpoint (change in HAMD scores from baseline to week 8) and key secondary endpoints will be analyzed using Bayesian methods, while other indicators will be analyzed using conventional statistical methods; Statistical software: SPSS 26.0 or R 4.0.0 will be used, with a two-tailed P-value \<0.05 considered statistically significant.

IX. Ethics and Confidentiality (A) Ethical Review The study protocol, informed consent form, and other subject-related documents must be approved in writing by the Ethics Committee of the Second Affiliated Hospital of Air Force Medical University before initiation; Annual progress reports will be submitted during the study period. Revisions to the protocol or informed consent form must be approved by the Ethics Committee (except for changes made to eliminate obvious and direct risks to subjects), with timely notification to the Ethics Committee in such cases; A final report will be submitted to the Ethics Committee upon study termination or completion.

(B) Informed Consent Patients or their legal representatives will be fully informed of the study purpose, interventions, potential benefits and risks, and rights and obligations. A copy of the ethical approval certificate will be provided; Sufficient time for consideration will be granted, and patients will be enrolled only after they or their legal representatives fully understand and voluntarily sign the written informed consent form; Updated versions of the informed consent form and relevant information will be provided to subjects during the study period if applicable.

(C) Confidentiality Measures All subject information will be anonymized with unique identifiers. Original data will be stored by designated personnel with restricted access; Only aggregated data will be presented in study publications or communications, with no disclosure of personal privacy information; Data access will be restricted to authorized institutions (e.g., government regulatory authorities, ethics committees) in accordance with regulations, adhering to relevant confidentiality laws.

X. Data Monitoring Committee Given the mild nature and low incidence of adverse events in this trial, along with its high safety profile, no independent Data Monitoring Committee will be established. Instead, an internal quality control team of the research group will conduct regular data verification and trial quality monitoring.

03

Conditions studied

  • Depressive Disorder (Per DSM-V Criteria, Mild-to-moderate)
  • Acute Coronary Syndrome (ACS)
  • Percutaneous Coronary Intervention (PCI)
  • Depressive Disorder
  • Postoperative Psychological Distress
  • Heart Rate Variability (HRV)
  • Inflammatory Factors
  • Randomized Controlled Trial (RCT)

Keywords

  • Transcutaneous Auricular Vagus Nerve Stimulation (taVNS)
  • Acute Coronary Syndrome (ACS)
  • Post-Percutaneous Coronary Intervention (PCI) Psychological Distress
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 years
  • Meeting the diagnostic criteria for ACS
  • 14 days to 12 months after successful PCI, with stable vital signs
  • Meeting the diagnostic criteria for depression according to the , Fifth Edition (DSM-V)
  • HAMD-17 score ≥7 and \<24 (mild-to-moderate depression), with HAMA score \<HAMD score;
  • Refusal of psychiatric consultation, antidepressant medication, or psychological therapy by the patient or their legal representative after full
  • Voluntary participation in the study and signing of the informed consent form

Exclusion criteria

Exclusion Criteria:

  • Severe heart failure ( [NYHA] class ≥III)
  • Uncontrolled hypertension (systolic blood pressure ≥180 mmHg and diastolic blood pressure ≥110 mmHg)
  • Electrocardiographic abnormalities (first-degree atrioventricular block with PR interval ≥0.20 s, second-degree type II or third-degree atrioventricular block at any time, 24-hour average heart rate ≤50 beats per minute, RR interval ≥3 s) or a history of syncope unrelated to the current ACS
  • Dialysis-dependent patients
  • Previous renal sympathetic denervation or vagal ganglion ablation
  • Expected survival time \<4 months
  • Pre-PCI diagnosis of severe mental illnesses, including schizophrenia, severe intellectual disability, or substance abuse
  • Current use of antipsychotic medications
  • High suicide risk
  • Pregnant or lactating women
  • Left ear diseases, acute exacerbation of asthma or , or other conditions precluding taVNS treatment
  • Implanted cardiac pacemaker, implantable cardioverter-defibrillator (ICD), or other implantable stimulators (e.g., vagus nerve stimulator, deep brain stimulator)
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    Transcutaneous Auricular Vagus Nerve Stimulation Intervention (taVNS)

    Participants in this arm receive the active transcutaneous auricular vagus nerve stimulation (taVNS) intervention as defined in the corresponding Intervention section. The intervention is administered twice daily for 20 minutes per session, continuously for 8 weeks, with weekly follow-up visits to assess depressive symptoms and stimulation safety.

    Device: Transcutaneous Auricular Vagus Nerve Stimulation (taVNS) Intervention

  • Sham comparator
    Sham Transcutaneous Auricular Vagus Nerve Stimulation Control(sham taVNS)

    Participants in this arm receive the sham transcutaneous auricular vagus nerve stimulation (sham taVNS) intervention as defined in the corresponding Intervention section. The sham intervention is delivered twice daily for 20 minutes per session over 8 weeks, matching the active group in procedure duration and frequency to maintain participant blinding, with weekly follow-up assessments identical to the active arm.

    Device: sham Transcutaneous Auricular Vagus Nerve Stimulation (taVNS) Control

Interventions

  • DeviceTranscutaneous Auricular Vagus Nerve Stimulation (taVNS) Intervention

    Transcutaneous auricular vagus nerve stimulation (taVNS) is delivered to the cymba conchae of the ear using a dedicated stimulator device, with parameters set as 20 Hz frequency, 0.5-3mA intensity, 20 minutes per session, twice daily for 8 weeks.

    Also known as: aVNS

  • Devicesham Transcutaneous Auricular Vagus Nerve Stimulation (taVNS) Control

    sham Transcutaneous Auricular Vagus Nerve Stimulation Control treatment with the same device of active stimulation group, wearing method, and parameter adjustments as active stimulation group However, stimulation will only be delivered for the first 5 seconds, with no subsequent electrical output. Treatment frequency will be identical to that of active stimulation group.

06

What researchers measure

Primary outcomes

  1. Change in depressive symptom severity as measured by the 17-item Hamilton Depression Rating Scale (HAMD-17) from baseline (Week 0) to Week 8

    The primary outcome is the change in total HAMD-17 scores from baseline (Week 0, prior to the initiation of transcutaneous auricular vagus nerve stimulation \[taVNS\] intervention) to the end of the 8-week taVNS intervention (Week 8). HAMD-17 scores range from 0 to 52, with higher scores indicating more severe depressive symptoms; a negative change score reflects a reduction in depressive symptom severity and clinical improvement. All assessments are conducted by trained clinicians who are masked to the participants' study group allocation (active taVNS vs. sham taVNS).

    Time frame: from baseline (Week 0) to Week 8

Secondary outcomes

  1. Change in 17-item Hamilton Depression Rating Scale (HAMD-17) scores at multiple time points from baseline (Week 0) to Week 16

    This outcome assesses the dynamic change in total HAMD-17 scores at baseline (Week 0), Week 4, Week 8 (end of intervention), and Week 16 (8-week follow-up post-intervention). HAMD-17 scores range from 0 to 52, with higher scores indicating more severe depressive symptoms; score reductions reflect sustained improvement in depressive symptoms post-intervention. Assessments are performed by blinded trained clinicians.

    Time frame: From baseline to week 16 (every 4 weeks)

  2. Change in Hamilton Anxiety Rating Scale (HAMA) scores from baseline (Week 0) to Week 16

    Change in Hamilton Anxiety Rating Scale (HAMA) scores from baseline (Week 0) to Week 16

    Time frame: From baseline to week 16 (every 4 weeks)

  3. Change in Generalized Anxiety Disorder 7-item (GAD-7) scale scores from baseline (Week 0) to Week 16

    This outcome evaluates the change in total GAD-7 scores at baseline (Week 0), Week 4, Week 8, and Week 16. GAD-7 is a self-reported scale with scores ranging from 0 to 21, where higher scores indicate more severe generalized anxiety symptoms; score changes reflect participants' self-perceived anxiety improvement.

    Time frame: From baseline to week 16 (every 4 weeks)

  4. Change in Beck Depression Inventory (BDI) scores from baseline (Week 0) to Week 16

    This outcome assesses the change in total BDI scores at baseline (Week 0), Week 4, Week 8, and Week 16. BDI is a self-reported depression scale with scores ranging from 0 to 63, with higher scores indicating more severe self-reported depressive symptoms; score reductions reflect participants' subjective improvement in depressive symptoms.

    Time frame: From baseline to week 16 (every 4 weeks)

  5. Change in Posttraumatic Stress Disorder Checklist (PCL) scores from baseline (Week 0) to Week 16

    This outcome measures the change in total PCL scores at baseline (Week 0), Week 4, Week 8, and Week 16. PCL scores range from 17 to 85 (per standard scoring), with higher scores indicating more severe posttraumatic stress symptoms; score changes reflect the effect of taVNS on comorbid PTSD symptoms (if present). Assessments are completed by participants via self-report.

    Time frame: From baseline to week 16 (every 4 weeks)

  6. Response rate based on the 17-item Hamilton Depression Rating Scale (HAMD-17)

    The response rate is defined as the proportion of participants who achieve a ≥50% reduction in the total HAMD-17 score from baseline to the specified time point. A higher response rate indicates a better improvement in depressive symptoms.

    Time frame: From baseline to week 16 (every 4 weeks)

  7. Remission rate based on the 17-item Hamilton Depression Rating Scale (HAMD-17)

    The remission rate is defined as the proportion of participants who achieve a total HAMD-17 score ≤7 points at the specified time point. A higher remission rate indicates a more complete resolution of depressive symptoms.

    Time frame: From baseline to week 16 (every 4 weeks)

  8. Change in Heart Rate Variability (HRV) parameters from baseline (Week 0) to Week 8

    This outcome assesses the change in HRV parameters (including SDNN, RMSSD, and HF/LF ratio) measured via electrocardiography (ECG) at baseline (Week 0) and Week 8 (end of intervention). HRV reflects autonomic nervous system function, with changes indicating the effect of taVNS on cardiac autonomic regulation.

    Time frame: Baseline (Week 0, pre-intervention), Week 8 (end of intervention)

  9. Change in N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels from baseline (Week 0) to Week 8

    This outcome measures the change in serum NT-proBNP levels (measured via enzyme-linked immunosorbent assay \[ELISA\]) at baseline (Week 0) and Week 8. NT-proBNP is a biomarker of cardiac stress and heart failure, with level changes reflecting the effect of taVNS on cardiac biochemical status.

    Time frame: Baseline (Week 0, pre-intervention), Week 8 (end of intervention)

  10. Change in peripheral inflammatory cytokine levels from baseline (Week 0) to Week 8

    This outcome evaluates the change in key peripheral inflammatory cytokines (including TNF-α, IL-6, IL-1β and hs-CRP) measured via ELISA at baseline (Week 0) and Week 8. Cytokine level changes reflect the effect of taVNS on systemic inflammatory status, which is associated with depression and cardiac health.

    Time frame: Baseline (Week 0, pre-intervention), Week 8 (end of intervention)

  11. Left Ventricular Ejection Fraction (LVEF) Measured by Echocardiography

    Left Ventricular Ejection Fraction (LVEF) is measured via transthoracic echocardiography, representing the percentage of blood ejected from the left ventricle during systole. It is a key indicator for evaluating left ventricular systolic function.

    Time frame: Week 0 (baseline), Week 8

  12. Left Ventricular End-Diastolic Diameter (LVEDD) Measured by Echocardiography

    Left Ventricular End-Diastolic Diameter (LVEDD) is determined by transthoracic echocardiography, referring to the internal diameter of the left ventricle at the end of diastole when the ventricle is filled with blood to the maximum extent. It reflects the diastolic capacity of the left ventricle.Week 0 (baseline), Week 8

    Time frame: Week 0 (baseline), Week 8

  13. Left Ventricular End-Systolic Diameter (LVESD) Measured by Echocardiography

    Left Ventricular End-Systolic Diameter (LVESD) is assessed by transthoracic echocardiography, denoting the internal diameter of the left ventricle at the end of systole when the ventricle contracts to the minimum volume. It is an important parameter for evaluating left ventricular contractile function.

    Time frame: Week 0 (baseline), Week 8

  14. Occurrence of Major Adverse Cardiovascular Events (MACE) from baseline (Week 0) to Week 16

    This outcome records the incidence of MACE (including myocardial infarction, stroke, hospitalization for heart failure, and cardiac death) from baseline (Week 0) to Week 16 (8-week follow-up post-intervention). MACE events are adjudicated by an independent clinical events committee blinded to study group allocation.

    Time frame: From baseline to week 16 (every 4 weeks)

  15. Quality of Life Score Measured by the 36-Item Short Form Health Survey (SF-36)

    The SF-36 scale is used to evaluate the quality of life of participants, covering 8 domains including physical functioning, role limitations due to physical health, bodily pain, general health perceptions, vitality, social functioning, role limitations due to emotional problems, and mental health. The total score ranges from 0 to 100, with higher scores indicating better quality of life.

    Time frame: From baseline to week 16 (every 4 weeks)

07

Study locations

1 of 1 sites recruiting
  • Tang-Du Hospital,Department of Cardiology
    Xi'an, Shaanxi 710038, China
    Recruiting
    • Wangang Guo, Doctor of Philosophy · ContactGuowagon@qq.com · 8618629581753
    • wangang Guo, Doctor of Philosophy · Principal investigator
    • Jing Han, Pursuing Master's Degree · Sub investigator
    • Haotian Zhe, Pursuing Master's Degree · Sub investigator
    • Huimiao Dai, Master's Degree · Sub investigator
    • Chuncheng Gao, Master's Degree · Sub investigator
    • Cheng Chen, Master's Degree · Sub investigator
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Individual participant data (IPD) generated from this trial will not be shared publicly. This decision is based on the need to protect the privacy of trial participants and comply with the requirements of the institutional review board (IRB) and relevant ethical guidelines.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2026 to primary completion in Jun 2026, 5 months.

Of 261 non-industry interventional studies with no phase under Depressive Disorder, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 45. This study's 5 months is below that.

Counting every sponsor, half of 276 studies reached it within 29 months; a quarter within 15 and three quarters within 45.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 5, 2026
First posted
Mar 6, 2026
StartActual
Jan 6, 2026
Primary completionActual
Jun 8, 2026
CompletionEst.
Aug 10, 2026
Last update
Jun 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07454070
Lead sponsor
Jing Han
Responsible party
Jing Han (Principal Investigator, Department of Cardiology, Tang-Du Hospital, Tang-Du Hospital) — Sponsor-investigator
First posted
Mar 6, 2026
Start date
Jan 6, 2026
Primary completion
Jun 8, 2026
Completion
Aug 10, 2026 (estimated)
Last update
Jun 16, 2026

Study contacts

jing Han, Pursuing Master's Degree
Contact
710694996@qq.com
8618506576253
wangang Guo, Doctor of Philosophy
Contact
Guowagon@qq.com
8618629581753
wangang Guo, Doctor of Philosophy
principal investigator · Department of Cardiology,Tang-Du Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion